Gov Scientist Says He Was Demoted For Opposing Trump’s Favorite Unproven COVID Drug

NANTONG, CHINA - FEBRUARY 27 2020: An employee checks the production of chloroquine phosphate, resumed after a 15-year break, in a pharmaceutical company in Nantong city in east China's Jiangsu province Thursday, Feb. 27, 2020. Chloroquine phosphate, an old drug for the treatment of malaria, has shown some efficacy and acceptable safety against COVID-19 associated pneumonia in trials, according to Chinese media.
NANTONG, CHINA - FEBRUARY 27 2020: An employee checks the production of chloroquine phosphate, resumed after a 15-year break, in a pharmaceutical company in Nantong city in east China's Jiangsu province Thursday, Feb... NANTONG, CHINA - FEBRUARY 27 2020: An employee checks the production of chloroquine phosphate, resumed after a 15-year break, in a pharmaceutical company in Nantong city in east China's Jiangsu province Thursday, Feb. 27, 2020. Chloroquine phosphate, an old drug for the treatment of malaria, has shown some efficacy and acceptable safety against COVID-19 associated pneumonia in trials, according to Chinese media.- PHOTOGRAPH BY Feature China / Barcroft Studios / Future Publishing (Photo credit should read Feature China/Barcroft Media via Getty Images) MORE LESS
Start your day with TPM.
Sign up for the Morning Memo newsletter

The recently demoted director of the federal agency leading COVID-19 research says he was given the boot because he insisted on thoroughly vetting the drug that President Donald Trump has sold as a miracle cure, hydroxychloroquine.

Dr. Rick Bright, a career government scientist, was until this week the director of the Biomedical Advanced Research and Development Authority (BARDA), which is housed in the Department of Health and Human Services. Stat News first reported Tuesday that Bright had been suddenly moved to a narrower role in the National Institutes of Health.

In a statement to the New York Times, Bright didn’t mince any words about the reasons for the demotion: He stood in the way of Trump’s favored potential COVID-19 treatment.

“I believe this transfer was in response to my insistence that the government invest the billions of dollars allocated by Congress to address the Covid-19 pandemic into safe and scientifically vetted solutions, and not in drugs, vaccines and other technologies that lack scientific merit,” Bright told the Times. “I am speaking out because to combat this deadly virus, science — not politics or cronyism — has to lead the way.”

“Specifically, and contrary to misguided directives, I limited the broad use of chloroquine and hydroxychloroquine, promoted by the administration as a panacea, but which clearly lack scientific merit,” Bright said.

The drugs are seen as potential therapies for COVID-19, but broad scientific proof to support their widespread use is nonexistent. A recent VA study was one of several that did not determine the drugs to be helpful against the viral disease.

Nonetheless, in recent weeks Trump has repeatedly promoted the drugs as potential globe-changing cures for the pandemic disease.

“I want them to try it,” the President said at a press conference earlier this month, one of many appeals for the unproven potential therapies. “And it may work, and it may not work. But if it doesn’t work, it’s nothing lost by doing it. Nothing.”

The FDA recently issued an unusual emergency authorization allowing BARDA to distribute hydroxychloroquine pills that it had been donated to hospitals for use with COVID-19 patients.

“While I am prepared to look at all options and to think ‘outside the box’ for effective treatments, I rightly resisted efforts to provide an unproven drug on demand to the American public,” Bright told the Times.

“I insisted that these drugs be provided only to hospitalized patients with confirmed Covid-19 while under the supervision of a physician,” he added, saying that he would request that the HHS inspector general investigate “the manner in which this administration has politicized the work of BARDA and has pressured me and other conscientious scientists to fund companies with political connections and efforts that lack scientific merit.”

“Rushing blindly towards unproven drugs can be disastrous and result in countless more deaths,” Bright said. “Science, in service to the health and safety of the American people, must always trump politics.”

Bright said in his statement that he clashed with HHS political leadership over vaccine investment and other matters, as well as “efforts to fund potentially dangerous drugs promoted by those with political connections,” though he did not specify who.

Latest News

Notable Replies

  1. It must give Donnie a Fright that Bright was Right.

  2. Impeachment Part Two: The Snake Oiling of HCQ.

  3. Avatar for caltg caltg says:

    Bright said in his statement that he clashed with HHS political leadership over vaccine investment and other matters, as well as “efforts to fund potentially dangerous drugs promoted by those with political connections,” though he did not specify who.

    Gee, I wonder who that might be. Does is rhyme with RUMP?

  4. Firing a scientist because he told the truth and has ethics. Yep. It’s pure Trump. Petty, mean spirited and entirely political. There’s no redeeming feature of this terrible man. None.

  5. Avatar for caltg caltg says:

    . . . not to mention criminally negligent with absolutely no regard for public safety and health.

Continue the discussion at forums.talkingpointsmemo.com

36 more replies

Participants

Avatar for discobot Avatar for mondfledermaus Avatar for pyanfar Avatar for epicurus Avatar for teenlaqueefa Avatar for dont Avatar for lastroth Avatar for ottnott Avatar for greylady Avatar for grandpajoe Avatar for fiftygigs Avatar for ljb860 Avatar for caltg Avatar for jmacaz Avatar for brian512 Avatar for corncaucus2008 Avatar for dannydorko Avatar for spin Avatar for cub_calloway Avatar for maximus Avatar for demosthenes59 Avatar for eyeball Avatar for rascal_crone Avatar for Volvo_Birkenstock

Continue Discussion
Masthead Masthead
Founder & Editor-in-Chief:
Executive Editor:
Managing Editor:
Deputy Editor:
Editor at Large:
General Counsel:
Publisher:
Head of Product:
Director of Technology:
Associate Publisher:
Front End Developer:
Senior Designer: